Expression of Programmed Death 1 Ligands by Murine T Cells and APC1

By Tomohide Yamazaki, H. Akiba, H. Iwai, H. Matsuda, M. Aoki, Yuka Tanno, T. Shin, H. Tsuchiya, D. Pardoll, K. Okumura and 2 more. Journal of Immunology, 2002

825 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/007c8acecb55d1fb616c312768173b58f870ec9e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Pardoll
2. Lieping Chen
3. G. Freeman
4. Arlene H. Sharpe
5. S. Topalian
6. B. Fife
7. J. Bluestone
8. Janis Taube

In Oncology

1. D. Pardoll
2. Lieping Chen
3. G. Freeman
4. Arlene H. Sharpe
5. S. Topalian
6. J. Bluestone
7. Janis Taube
8. B. Fife

Citations in the corpus

• PD-1 and its ligands in tolerance and immunity. (2008, background): “Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism.”
• Regulatory mechanisms of PD-1/PD-L1 in cancers (2024, background): “PD-L1 is widely expressed in antigen-presenting cells and tissues, such as heart and lung [2, 3].”
• Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways (2008, background): “PD-L1 is expressed on leukocytes, nonhematopoietic cells, and in non-lymphoid tissues including islets (21, 24, 25), while PD-L2 is expressed exclusively on DCs and monocytes (21, 22, 26, 27).”
• The Pathogenesis of Sepsis (2011, background): “PD-L2 is more restricted and is inducible only on dendritic cells, macrophages, bone marrow–derived mast cells, and specific peritoneal B cells (31, 32).”
• Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014, background): “PD-1 also binds PD-L2 (B7-DC), which is expressed selectively on macrophages and dendritic cells ((7-9)).”
• The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice (2003, methodology): “The anti–mouse PD-L1 mAb (MIH6, rat IgG2a) and the anti–mouse PD-L2 mAb (TY25, rat IgG2a) were generated as recently described (15).”